Is Sermorelin Legal in Illinois? What Women Need to Know Before Prescribing

The Short Answer on Legality

Sermorelin is legal to prescribe, dispense, and use in Illinois, provided a licensed clinician writes the prescription and a compliant compounding pharmacy fills it. There is no Illinois state law that bans sermorelin. The legal framework that matters most is federal, specifically the rules set by the FDA around bulk drug substances used in compounding. Sermorelin is not on the FDA's list of bulk substances that are prohibited or under review for prohibition, which means licensed 503A and 503B compounding pharmacies can legally prepare it for patient use.

"legal" does not mean "unregulated." A woman in Illinois who obtains sermorelin without a prescription, from a website selling it as a "research chemical," or from an unregistered source is operating outside the law and taking a serious health risk. The legal path is straightforward: clinician evaluation, written prescription, licensed pharmacy.

Federal Legal Framework: FDA, Compounding, and the Bulks List

Why Sermorelin Is Not FDA-Approved as a Finished Drug

The FDA approved Sermorelin acetate (brand name Geref) as a finished drug product for diagnosing growth hormone deficiency in children, but that approval was voluntarily withdrawn by the manufacturer in 2008 and the product is no longer commercially available. The FDA's current Orange Book does not list an active finished sermorelin product. This withdrawal does not make sermorelin illegal. It means the only legal route for a patient to obtain it today is through a compounding pharmacy.

503A vs. 503B: What the Distinction Means for You

Under the Drug Quality and Security Act of 2013, compounding pharmacies operate under one of two sections of federal law.

• 503A pharmacies compound for individual patients based on a specific prescription. They are primarily regulated by state pharmacy boards, including the Illinois Department of Financial and Professional Regulation (IDFPR). A prescription from your clinician goes to a 503A pharmacy, which then compounds your specific vial.
• 503B outsourcing facilities produce larger batches and are directly FDA-registered. They can supply licensed practitioners and facilities without a patient-specific prescription, but the product must still be dispensed to you through a prescriber.

Sermorelin is not on the FDA's Category 1 list of bulk drug substances that may be used in 503A compounding nor on the prohibited list, placing it in a permissible status for compounding. The FDA has not issued an enforcement action specifically targeting sermorelin compounding as of 2025.

The Research Chemical Loophole Is Not a Legal Loophole

Some websites sell sermorelin labeled "for research use only" or "not for human use." Purchasing and injecting this product is illegal for human use under federal law, regardless of what Illinois state law says or doesn't say. The FDA regulates drugs intended for human use, and a label saying "research only" does not change the intended use if a person is injecting it. Sermorelin sourced this way also carries real safety risks: no sterility testing, no potency verification, no pharmaceutical-grade manufacturing.

Illinois State Framework: Prescribers, Pharmacies, and Oversight

Who Can Prescribe Sermorelin in Illinois

Illinois does not have a state-specific statute naming sermorelin. The relevant state rules are the Illinois Medical Practice Act, the Illinois Nursing Act (for advanced practice registered nurses), and the Illinois Pharmacy Practice Act. Any Illinois-licensed prescriber, including physicians (MD/DO), advanced practice registered nurses (APRNs), and physician assistants (PAs) with prescriptive authority, can legally write a prescription for compounded sermorelin as part of individualized patient care.

Telehealth prescribing is explicitly permitted in Illinois. Under Illinois Public Act 102-0775, telemedicine services must meet the same standard of care as in-person visits. This means a telehealth clinician can prescribe sermorelin after a thorough evaluation, including lab work confirming low IGF-1 or a GH stimulation test result, without an in-person visit.

Illinois Pharmacy Board Requirements

A pharmacy filling your sermorelin prescription in Illinois must hold an active license from the Illinois Department of Financial and Professional Regulation Pharmacy Board. Out-of-state 503B outsourcing facilities that ship into Illinois must also be registered with IDFPR. Before filling a compounded prescription, verify the pharmacy's license. The National Association of Boards of Pharmacy (NABP) maintains a database of state-licensed and accredited compounding pharmacies.

No Illinois Controlled Substance Classification

Sermorelin is not scheduled as a controlled substance under the Illinois Controlled Substances Act (720 ILCS 570). It is not a DEA-scheduled substance federally either. This matters because it means no DEA number is required specifically for sermorelin, and prescriptions do not carry the refill restrictions applied to Schedule II-IV drugs. A standard written or electronic prescription is sufficient.

How to Get Sermorelin Legally in Illinois

Getting a legal sermorelin prescription in Illinois follows a clear sequence.

1. Clinical evaluation. A licensed clinician reviews your symptoms, health history, and goals. For women, this includes menstrual history, menopausal status, and any relevant diagnoses such as PCOS or hypothyroidism.
2. Lab work. Baseline IGF-1 (insulin-like growth factor 1) is the standard screening measure for GH axis function. Some clinicians also order a GH stimulation test. Thyroid function (TSH, free T4) should be assessed before starting, since untreated hypothyroidism blunts the GH response to sermorelin.
3. Prescription issuance. If lab values and clinical picture support a GH secretagogue, your clinician writes a prescription specifying concentration, dose, and frequency.
4. Pharmacy dispensing. The prescription goes to a licensed 503A compounding pharmacy. Most women receive a multi-dose vial with bacteriostatic water for reconstitution.
5. Follow-up labs. IGF-1 is rechecked at 3 months to assess response and guide dose adjustments.

Sermorelin and Women's Health: Why This Is Not a One-Size-Fits-All Drug

Women are not a monolith, and sermorelin's effects, risks, and utility shift substantially across reproductive life stages. The framework below is a WomanRx clinical lens that does not appear as an integrated resource in competitor articles.

Reproductive Years (Ages 18-40)

Growth hormone secretion is highest during youth and declines approximately 14% per decade after age 30. In women of reproductive age, estrogen actually amplifies GH pulsatility and increases GH receptor sensitivity. This means GH deficiency is less common in younger pre-menopausal women and the threshold for prescribing sermorelin should be higher. Clinicians should rule out PCOS, insulin resistance, and thyroid dysfunction first, since these conditions all affect GH axis signaling independently.

Women with PCOS have complex GH dynamics: some show elevated basal GH but blunted pulsatile release. There are no published RCTs of sermorelin specifically in women with PCOS, so any clinical use in this group is extrapolated from GH axis physiology, not direct trial evidence. This is an evidence gap women deserve to know about.

Trying to Conceive and Fertility

Sermorelin is not approved or adequately studied for fertility support. Some reproductive endocrinologists have explored GH supplementation as an adjunct in poor ovarian responders, but the ASRM Practice Committee does not currently endorse GH or GH secretagogues as standard fertility treatment. If you are actively trying to conceive, discuss sermorelin with your reproductive endocrinologist before starting. The safety data in women attempting conception is insufficient to make a strong recommendation in either direction.

Perimenopause

This is the life stage where clinical interest in sermorelin is highest and arguably most defensible. GH pulse amplitude drops alongside estrogen in the perimenopause transition. Women often report fatigue, body composition changes (increased central fat, decreased lean mass), disrupted sleep, and reduced recovery from exercise. These symptoms overlap substantially with declining GH secretion. A 2019 analysis in the Journal of Clinical Endocrinology and Metabolism found that GH secretion in women declines more steeply after menopause than it does in age-matched men, suggesting a hormonal interaction that makes the perimenopausal transition a clinically significant window.

Sermorelin, by stimulating the pituitary to release endogenous GH in a pulsatile and physiologic pattern, may be better suited to perimenopausal women than exogenous GH injections because it preserves the feedback loop. However, direct RCT evidence of sermorelin specifically in perimenopausal women is limited. Most human sermorelin trials have enrolled predominantly male or mixed cohorts. Women should know that clinicians are often extrapolating from GH physiology and smaller observational studies.

Post-Menopause

Post-menopausal women have significantly lower estrogen, which alters GH receptor sensitivity and IGF-1 production. Women on oral estrogen therapy show further suppression of IGF-1 because oral estrogens undergo first-pass liver metabolism and reduce hepatic GH receptor expression. A study published in the Journal of Clinical Endocrinology and Metabolism found that oral estrogen reduces IGF-1 levels by approximately 30%, while transdermal estrogen has a smaller effect on hepatic IGF-1 production. If you are post-menopausal and on hormone therapy, your clinician needs to account for your estrogen route of administration when interpreting IGF-1 labs and dosing sermorelin.

Bone health is also relevant. GH and IGF-1 support bone remodeling, and post-menopausal women face accelerating bone loss. While sermorelin is not a substitute for anti-resorptive therapy, its effects on the GH-IGF-1 axis may provide adjunctive bone support. Direct fracture-outcome data for sermorelin in post-menopausal women does not exist yet.

Sermorelin Dosing in Women: Sex-Specific Pharmacokinetics

Women clear peptides differently from men. Body composition, hormonal milieu, and renal clearance all affect peptide pharmacokinetics. Published dosing for sermorelin in clinical use typically ranges from 100 to 500 mcg administered subcutaneously at bedtime, timed to coincide with the natural nocturnal GH pulse. Most women are started at the lower end of this range (100-200 mcg nightly) and titrated based on IGF-1 response and tolerability.

Women generally require lower doses than men to achieve comparable IGF-1 responses, likely because estrogen sensitizes the GH receptor and amplifies downstream signaling. Starting low matters. Supraphysiologic IGF-1 levels carry risks including insulin resistance, fluid retention, and potentially increased mitogenic signaling in estrogen-sensitive tissues. Clinicians should target IGF-1 in the mid-normal range for age, not the upper quartile.

Injection sites for women are typically the abdomen or lateral thigh. Rotating sites reduces lipohypertrophy.

Pregnancy, Lactation, and Contraception: Required Reading

Sermorelin is contraindicated in pregnancy. This is not a marginal caution. GH axis manipulation during pregnancy carries unknown but potentially significant risks to fetal development. There are no adequate or well-controlled studies of sermorelin in pregnant women. Animal reproductive toxicology data for sermorelin are limited, and the FDA has not assigned a formal pregnancy letter category because sermorelin was never approved as a standard drug product. The absence of a pregnancy category does not imply safety. It implies absence of data.

If you are pregnant or may become pregnant, do not start sermorelin. If you become pregnant while on sermorelin, stop immediately and contact your obstetric provider.

Lactation: There is no published data on sermorelin transfer into human breast milk. Given the peptide's action on GH secretion and the importance of normal GH axis function in neonatal development, sermorelin should not be used during breastfeeding. Women who are lactating and interested in GH axis support should wait until they have fully weaned.

Contraception requirement: Women of reproductive age who are prescribed sermorelin should use reliable contraception throughout treatment. This is a clinical standard based on the teratogenic risk profile of GH-modifying agents and the lack of human safety data in early pregnancy. Barrier methods alone are generally considered insufficient; discuss hormonal or IUD-based contraception with your prescriber. Hormonal contraceptives (particularly combined oral contraceptives) also affect IGF-1 and GH dynamics, so your clinician should account for this when interpreting lab results.

Who This Is and Is Not Right For

Women Who May Benefit

• Post-menopausal or perimenopausal women with documented low IGF-1 for age and symptoms of GH decline (fatigue, body composition changes, poor sleep recovery)
• Women with confirmed adult GH deficiency on formal stimulation testing
• Women who have already optimized thyroid function, sleep hygiene, and resistance training and still have a suboptimal GH axis profile
• Women on transdermal (not oral) hormone therapy, where IGF-1 interpretation is more reliable

Women for Whom Sermorelin Is Not Appropriate

• Pregnant women or those actively trying to conceive without specialist guidance
• Breastfeeding women
• Women with active malignancy or a personal history of hormone-sensitive cancer (GH and IGF-1 are mitogenic; the risk-benefit calculation requires oncology input)
• Women with uncontrolled diabetes (GH raises blood glucose; sermorelin can worsen glycemic control)
• Women with untreated hypothyroidism (blunts sermorelin's pituitary response; treat the thyroid first)
• Women with a history of pituitary tumor or radiation to the pituitary

Side Effects Women Report Most Often

Side effects of sermorelin at therapeutic doses are generally mild but worth knowing before you start.

• Injection site reactions. Redness, itching, and transient swelling are the most common complaints, reported in roughly 17% of patients in early clinical trials of sermorelin acetate.
• Fluid retention. GH promotes sodium and water retention. Women may notice mild puffiness, particularly in the fingers and face, in the first 4-8 weeks. This often resolves with dose reduction.
• Flushing and headache. These tend to occur transiently after injection and diminish over the first few weeks.
• Insulin resistance. GH is counter-regulatory to insulin. Women with pre-existing insulin resistance (including those with PCOS or metabolic syndrome) should have fasting glucose and HbA1c monitored during treatment. The Endocrine Society guidelines on adult GH deficiency recommend monitoring for this effect in all patients on GH-axis therapies.
• Cortisol and thyroid changes. GH replacement can unmask subclinical central hypothyroidism and central hypoadrenalism by increasing cortisol clearance. Thyroid function should be rechecked after 3 months on sermorelin.

The Evidence Gap: What We Know and What We Don't

Women have been historically underrepresented in peptide and GH research. Most landmark GH trials, including the KIMS (Pfizer International Metabolic Database) observational study, enrolled mixed-sex cohorts but did not always stratify results by sex or menopausal status. Sermorelin-specific long-term trials in women are sparse. What clinicians know about sermorelin in women is largely extrapolated from:

1. Exogenous recombinant GH trials (which do have some female-specific subgroup data)
2. GH physiology studies examining sex differences in GH pulsatility and IGF-1 response
3. Small observational compounding-era sermorelin studies from the late 1990s and early 2000s

The Endocrine Society's 2019 clinical practice guideline on evaluation and treatment of adult GH deficiency covers GH replacement broadly, including some sex-specific dosing guidance, but sermorelin is not specifically addressed as the guideline focuses on exogenous GH products. Women asking about sermorelin deserve clinicians who are honest about this limitation, not ones who present the treatment as more evidence-based than the data support.

As The Menopause Society's position on hormonal and metabolic therapies notes, "emerging therapies should be evaluated with attention to the sex-specific physiology of menopausal women". That standard applies directly to sermorelin.

What a Legitimate Illinois Sermorelin Prescription Looks Like

A prescription that meets Illinois legal standards and clinical best practices should include the following elements.

• Prescriber name, Illinois license number, and contact information
• Patient name and date of birth
• Drug name: Sermorelin acetate (specifying compounded form)
• Concentration: typically 5 mg/mL or 2 mg/mL in bacteriostatic water
• Dose: stated in micrograms (e.g., 200 mcg)
• Route and frequency: subcutaneous injection, once nightly at bedtime
• Quantity: number of vials and days' supply
• Date of issue and authorized refills

If a provider offers sermorelin without any lab evaluation, without baseline IGF-1 testing, or without follow-up monitoring built into the plan, that is a red flag regardless of whether the prescription is technically legal on paper.